



 **Nplate<sup>®</sup> elevates  
her chance for  
treatment-free  
remission<sup>\*,1</sup>**

**Nplate<sup>®</sup> early  
ITP indication\*  
provides an  
opportunity to  
improve chances  
of remission<sup>1-4</sup>**

1. Nplate<sup>®</sup> (romiplostim) Summary of Product Characteristics. Last update: January 2021. 2. Lozano ML, et al. Sci Rep. 2019;9(1):16680. 3. Kuter DJ, et al. Br J Haematol. 2019;185(3):503-13. 4. Lozano ML, et al. Expert Rev Hematol. 2020;13(12):1319-32. 5. Provan D, et al. Blood Adv. 2019;3(22):3780-817. 6. Neunert C, et al. Blood Adv. 2019;3(23):3829-66. 7. Matzdorff A, et al. Oncol Res Treat. 2018;41:1-30. 7. 8. Revolade<sup>®</sup> (eltrombopag) Summary of Product Characteristics. Last update: February 2021. 9. Doptelet<sup>®</sup> (avatrombopag) Summary of Product Characteristics. Last update: April 2021.

Nplate<sup>®</sup> is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). Nplate<sup>®</sup> is also indicated for the treatment of chronic primary ITP in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

API available Upon Request

PR-NPL-UAE-000016-10-2021

**AMGEN<sup>®</sup>**

Amgen Middle East FZZ-LC  
Business Central Tower building A, Office 2007.  
P.O. Box 502607, Dubai Media City, Dubai, UAE.



**OUR MISSION IS REMISSION**